Drug General Information |
Drug ID |
D0D2FC
|
Former ID |
DIB019118
|
Drug Name |
CGP74514A
|
Synonyms |
CGP-74514A; CGP 74514A
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
|
Formula |
C19H24ClN7
|
InChI |
InChI=1S/C19H24ClN7/c1-2-27-11-22-16-17(23-13-7-5-6-12(20)10-13)25-19(26-18(16)27)24-15-9-4-3-8-14(15)21/h5-7,10-11,14-15H,2-4,8-9,21H2,1H3,(H2,23,24,25,26)/t14-,15+/m0/s1
|
InChIKey |
UTBSBSOBZHXMHI-LSDHHAIUSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
3249314, 8322612, 10319010, 15425232, 26758395, 39889300, 47425334, 47500565, 50111006, 53790513, 57409997, 79148069, 85787139, 90341623, 99302651, 103024429, 103433116, 103967051, 111440920, 124749601, 124879618, 124879619, 124879620, 124879621, 135896297, 137244748, 139404166, 163688441, 172649609, 178102568, 179236122, 198986007, 231624453
|
Target and Pathway |
Target(s) |
Cell division control protein 2 homolog |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
Cell cycle
|
Oocyte meiosis
|
p53 signaling pathway
|
Gap junction
|
Progesterone-mediated oocyte maturation
|
Herpes simplex infection
|
Epstein-Barr virus infection
|
Viral carcinogenesis
|
NetPath Pathway
|
RANKL Signaling Pathway
|
Pathway Interaction Database
|
p73 transcription factor network
|
E2F transcription factor network
|
PLK1 signaling events
|
AP-1 transcription factor network
|
FOXM1 transcription factor network
|
Retinoic acid receptors-mediated signaling
|
Reactome
|
MAPK3 (ERK1) activation
|
E2F mediated regulation of DNA replication
|
G0 and Early G1
|
Cyclin B2 mediated events
|
Golgi Cisternae Pericentriolar Stack Reorganization
|
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
Regulation of APC/C activators between G1/S and early anaphase
|
Phosphorylation of the APC/C
|
Phosphorylation of Emi1
|
Condensation of Prophase Chromosomes
|
MASTL Facilitates Mitotic Progression
|
Resolution of Sister Chromatid Cohesion
|
Condensation of Prometaphase Chromosomes
|
Regulation of PLK1 Activity at G2/M Transition
|
Activation of NIMA Kinases NEK9, NEK6, NEK7
|
Loss of Nlp from mitotic centrosomes
|
Recruitment of mitotic centrosome proteins and complexes
|
Loss of proteins required for interphase microtubule organization?from the centrosome
|
Recruitment of NuMA to mitotic centrosomes
|
Depolymerisation of the Nuclear Lamina
|
Anchoring of the basal body to the plasma membrane
|
MAPK6/MAPK4 signaling
|
G1/S-Specific Transcription
|
Cyclin A/B1 associated events during G2/M transition
|
G2/M DNA replication checkpoint
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
|
WikiPathways
|
DNA Damage Response
|
G1 to S cell cycle control
|
TGF beta Signaling Pathway
|
PPAR Alpha Pathway
|
MAP kinase activation in TLR cascade
|
RAF/MAP kinase cascade
|
Mitotic Prophase
|
Mitotic Prometaphase
|
BMI1
|
ATM Signaling Pathway
|
Retinoblastoma (RB) in Cancer
|
Spinal Cord Injury
|
Prostate Cancer
|
Regulation of Microtubule Cytoskeleton
|
Integrated Cancer pathway
|
Mitotic G2-G2/M phases
|
Mitotic G1-G1/S phases
|
Cell Cycle
|
APC/C-mediated degradation of cell cycle proteins
|
Cell Cycle Checkpoints
|
miRNA Regulation of DNA Damage Response
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5945). |
---|
REF 2 | 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6. |